Literature DB >> 825360

Cephalotaxine esters in the treatment of acute leukemia. A preliminary clinical assessment.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 825360

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN： 0366-6999            Impact factor:   2.628


× No keyword cloud information.
  23 in total

1.  Pharmacokinetics of homoharringtonine in dogs.

Authors:  K Lu; N Savaraj; L G Feun; Z G Guo; T Umsawasdi; T L Loo
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

2.  New natural products of interest under development at the National Cancer Institute.

Authors:  J Douros; M Suffness
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

Review 3.  Homoharringtonine/omacetaxine mepesuccinate: the long and winding road to food and drug administration approval.

Authors:  Hagop M Kantarjian; Susan O'Brien; Jorge Cortes
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-06-20

4.  Low dose of homoharringtonine and cytarabine combined with granulocyte colony-stimulating factor priming on the outcome of relapsed or refractory acute myeloid leukemia.

Authors:  Liu-Fang Gu; Wang-Gang Zhang; Fang-Xia Wang; Xing-Mei Cao; Yin-Xia Chen; Ai-Li He; Jie Liu; Xiao-Rong Ma
Journal:  J Cancer Res Clin Oncol       Date:  2010-12-09       Impact factor: 4.553

5.  Efficacy and safety of CHG regimen (low-dose cytarabine, homoharringtonine with G-CSF priming) as induction chemotherapy for elderly patients with high-risk MDS or AML transformed from MDS.

Authors:  Lingyun Wu; Xiao Li; Jiying Su; Qi He; Xi Zhang; Chunkang Chang; Quan Pu
Journal:  J Cancer Res Clin Oncol       Date:  2011-08-04       Impact factor: 4.553

6.  Homoharringtonine: a phase I evaluation.

Authors:  J A Stewart; I H Krakoff
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

7.  A phase II open-label study of the intravenous administration of homoharringtonine in the treatment of myelodysplastic syndrome.

Authors:  N Daver; A Vega-Ruiz; H M Kantarjian; Z Estrov; A Ferrajoli; S Kornblau; S Verstovsek; G Garcia-Manero; J E Cortes
Journal:  Eur J Cancer Care (Engl)       Date:  2013-05-23       Impact factor: 2.520

8.  Biologic and pharmacologic effects of harringtonine on human leukemia-lymphoma cells.

Authors:  Y Takemura; T Ohnuma; T C Chou; T Okano; J F Holland
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

9.  Effects of harringtonine in combination with acivicin, adriamycin, L-asparaginase, cytosine arabinoside, dexamethasone, fluorouracil or methotrexate on human acute myelogenous leukemia cell line KG-1.

Authors:  T Okano; T Ohnuma; J F Holland; H P Koeffler; H Jui
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

10.  Homoharringtonine binds to and increases myosin-9 in myeloid leukaemia.

Authors:  Ting Zhang; Shuijie Shen; Zhijuan Zhu; Shasha Lu; Xiufeng Yin; Jiang Zheng; Jie Jin
Journal:  Br J Pharmacol       Date:  2015-12-01       Impact factor: 8.739
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.